Ann Cardiovasc Surg | Volume 1, Issue 3 | Research Article | Open Access

Fibrinolysis in Acute Myocardial Infarction; State of the Art

Hadi AR Khafaji*

Department of Cardiology, Saint Michael’s- Toronto University, Canada

*Correspondance to: Hadi AR Hadi Khafaji 

Fulltext PDF


The treatment of ST-Elevation Myocardial Infarction (STEMI) has endured striking expansions over the past three decades. Current practice guidelines are acquainted with the importance of promptly restoring normal coronary blood flow in infarct related artery. In principle, pharmacologic or mechanical strategies might be considered for reperfusion and this is based on multiple randomized controlled trials. National registries for acute myocardial infarction are also important as they offer data that are unique for that specific community or country and could contribute to the optimal use of reperfusion therapies in that region. In this review article we summarize data based on the available studies conducted over the past last 30 years about pharmacologic reperfusion therapy and compare it with primary angioplasty coronary intervention.


Fibrinolytic agents; Streptokinase; Retaplase; Alteplase; Tenecteplase; Acute myocardial infarction


Hadi AR Khafaji. Fibrinolysis in Acute Myocardial Infarction; State of the Art. Ann Cardiovasc Surg. 2018; 1(3): 1015.

Subscribe to Our Newsletter